CSIRO Publishing blank image blank image blank image blank imageBooksblank image blank image blank image blank imageJournalsblank image blank image blank image blank imageAbout Usblank image blank image blank image blank imageShopping Cartblank image blank image blank image You are here: Journals > Sexual Health   
Sexual Health
Journal Banner
  Publishing on sexual health from the widest perspective
blank image Search
blank image blank image
blank image
  Advanced Search

Journal Home
About the Journal
Editorial Structure
For Advertisers
Online Early
Current Issue
Just Accepted
All Issues
Special Issues
Sample Issue
For Authors
General Information
Submit Article
Author Instructions
Open Access
For Referees
Referee Guidelines
Review an Article
Annual Referee Index
For Subscribers
Subscription Prices
Customer Service
Library Recommendation

blue arrow e-Alerts
blank image
Subscribe to our Email Alert or RSS feeds for the latest journal papers.

red arrow Connect with us
blank image
facebook twitter logo LinkedIn

red arrow Interview with Kit Fairley
blank image
Hear Kit Fairley speak about what is sexual health.


Article << Previous     |     Next >>   Contents Vol 11(2)

Predicting the population impact of increased HIV testing and treatment in Australia

James Jansson A, Cliff C. Kerr A and David P. Wilson A B

A The Kirby Institute, University of New South Wales, Sydney, NSW 2010, Australia.
B Corresponding author. Email: dwilson@kirby.unsw.edu.au

Sexual Health 11(2) 146-154 http://dx.doi.org/10.1071/SH13069
Submitted: 3 May 2013  Accepted: 30 October 2013   Published: 7 February 2014

PDF (655 KB) $25
 Supplementary Material
 Export Citation

Introduction: The treatment as prevention strategy has gained popularity as a way to reduce the incidence of HIV by suppressing viral load such that transmission risk is decreased. The effectiveness of the strategy also requires early diagnosis. Methods: Informed by data on the influence of diagnosis and treatment on reducing transmission risk, a model simulated the impact of increasing testing and treatment rates on the expected incidence of HIV in Australia under varying assumptions of treatment efficacy and risk compensation. The model utilises Australia’s National HIV Registry data, and simulates disease progression, testing, treatment, transmission and mortality. Results: Decreasing the average time between infection and diagnosis by 30% is expected to reduce population incidence by 12% (~126 cases per year, 95% confidence interval (CI): 82–198). Treatment of all people living with HIV with CD4 counts <500 cells μL–1 is expected to reduce new infections by 30.9% (95% CI: 15.9–37.6%) at 96% efficacy if no risk compensation occurs. The number of infections could increase up to 12.9% (95% CI: 20.1–7.4%) at 26% efficacy if a return to prediagnosis risk levels occur. Conclusion: Treatment as prevention has the potential to prevent HIV infections but its effectiveness depends on the efficacy outside trial settings among men who have sex with men and the level of risk compensation. If antiretroviral therapy has high efficacy, risk compensation will not greatly change the number of infections. If the efficacy of antiretroviral therapy is low, risk compensation could lead to increased infections.

Additional keywords: efficacy, mathematical model, prevention, risk compensation, treatment as prevention, viral load.


[1]  Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 2011; 9: 446–69.
CrossRef | CAS | PubMed |

[2]  Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372: 314–20.
CrossRef | PubMed |

[3]  Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen R, et al Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921–9.
CrossRef | CAS | CAS | PubMed |

[4]  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493–505.
CrossRef | CAS | CAS | PubMed |

[5]  Castilla J, del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40: 96–101.
CrossRef | PubMed |

[6]  Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339: 966–71.
CrossRef | CAS | CAS | PubMed |

[7]  Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet 2013; 382: 1195–203.
| PubMed |

[8]  Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med 2012; 9: e1001231.
CrossRef | PubMed |

[9]  Birrell PJ, Gill ON, Delpech VC, Brown AE, Desai S, Chadborne TR, et al HIV incidence in men who have sex with men in England and Wales 2001–10: a nationwide population study. Lancet Infect Dis 2013; 13: 313–8.
CrossRef | PubMed |

[10]  Sullivan PS, Hamouda O, Delpech V, Geduld JE, Prejean J, Semaille C, et al Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996–2005. Ann Epidemiol 2009; 19: 423–31.
CrossRef | PubMed |

[11]  Das M, Chu PL, Santos G-M, Scheer S, Vittinghoff E, McFarland W, et al Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010; 5: e11068.
CrossRef | PubMed |

[12]  Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376: 532–9.
CrossRef |

[13]  Grulich AE, Wilson DP. Is antiretroviral therapy modifying the HIV epidemic? Lancet 2010; 376: 1824.
CrossRef | PubMed |

[14]  Steward WT, Remien RH, Higgins JA, Dubrow R, Pinkerton SD, Sikkema KJ, et al Behavior change following diagnosis with acute/early HIV infection – a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav 2009; 13: 1054–60.
CrossRef | PubMed |

[15]  Metsch LR, Pereyra M, Messinger S, del Rio C, Strathdee SA, Anderson-Mahoney P, et al HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis 2008; 47: 577–84.
CrossRef | PubMed |

[16]  Fox J, White PJ, Macdonald N, Weber J, McClure M, Fidler S, et al Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med 2009; 10: 432–8.
CrossRef | PubMed |

[17]  Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39: 446–53.
CrossRef | PubMed |

[18]  Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48–57.
CrossRef | PubMed |

[19]  Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, et al HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012; 9: e1001245.
CrossRef | PubMed |

[20]  Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, et al Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS ONE 2013; 8: e55312.
CrossRef | CAS | CAS | PubMed |

[21]  Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, et al CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS 2010; 24: 2697–704.
CrossRef | CAS | CAS | PubMed |

[22]  Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946–54.
CrossRef | CAS | CAS | PubMed |

[23]  Australian Government Actuary (AGA). Australian life tables 2005–07. Canberra: AGA; 2009.

[24]  Nakhaee F, Black D, Wand H, McDonald A, Law M. Changes in mortality following HIV and AIDS and estimation of the number of people living with diagnosed HIV/AIDS in Australia, 1981–2003. Sex Health 2009; 6: 129–34.
CrossRef | PubMed |

[25]  Falster K, Gelgor L, Shaik A, Zablotska I, Prestage G, Grierson J, et al Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment. Sex Health 2008; 5: 141–54.
CrossRef | PubMed |

[26]  Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, et al Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010; 50: 264–71.
CrossRef | PubMed |

[27]  Mao L, Kippax SC, Holt M, Prestage GP, Zablotska IB, , de Wit JBF. Rates of condom and non-condom-based anal intercourse practices among homosexually active men in Australia: deliberate HIV risk reduction? Sex Transm Infect 2011; 87: 489–93.
CrossRef | PubMed |

[28]  Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292: 224–36.
CrossRef | CAS | CAS | PubMed |

[29]  The Kirby Institute. AHOD HIV observational database annual report 2012. Sydney: The Kirby Institute, The University of New South Wales; 2012.

[30]  Holt M, Mao L, Prestage G, Zablotska I, de Wit J. Gay community periodic surveys: national report 2010. Sydney: National Centre in HIV Social Research, The University of New South Wales; 2010.

[31]  Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 1990; 3: 144–51.
| CAS |
| CAS | PubMed |

[32]  Van de Ven P, Mao L, Fogarty A, Rawstorne P, Crawford J, Prestage G, et al Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005; 19: 179–84.
CrossRef | PubMed |

[33]  Jin F, Prestage GP, Ellard J, Kippax SC, Kaldor JM, Grulich A. How homosexual men believe they became infected with HIV: the role of risk-reduction behaviors. J Acquir Immune Defic Syndr 2007; 46: 245–7.
CrossRef | PubMed | PubMed |

[34]  Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287: 650–4.
CrossRef | CAS | CAS | PubMed | PubMed |

[35]  The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia annual surveillance report 2012. Sydney: The Kirby Institute, the University of New South Wales; 2012.

[36]  Mao L, de Wit J, Adam P, Post JJ, Crooks L, Kidd MR, et al Australian prescribers’ perspectives on ART initiation in the era of “treatment as prevention”. AIDS Care 2013; 25: 1375–9.
CrossRef | PubMed | PubMed |

[37]  Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 2009; 373: 9–11.
CrossRef | PubMed | PubMed |

[38]  Babiker AG, Emery S, Fätkenheuer G, Gordin FM, Grund B, Lundgren JD, et al Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10: .
CrossRef | PubMed | PubMed |

[39]  Gray RT, Prestage GP, Down I, Ghaus MH, Hoare A, Bradley J, et al Increased HIV testing will modestly reduce HIV incidence among gay men in NSW and would be acceptable if HIV testing becomes convenient. PLoS ONE 2013; 8: e55449.
CrossRef | CAS | CAS | PubMed | PubMed |

[40]  Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815–26.
CrossRef | CAS | CAS | PubMed | PubMed |

[41]  When to Start Consortium Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352–63.
CrossRef | PubMed | PubMed |

[42]  Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci D, et al Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23: 1743–53.
CrossRef | PubMed | PubMed |

[43]  Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, , MacArthur RD, et al CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841–8.
CrossRef | PubMed | PubMed |

[44]  Guiguet M, Boué F, Cadranel J, Lang J-M, Rosenthal E, Costagliola D, et al Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 1152–9.
CrossRef | CAS | CAS | PubMed | PubMed |

[45]  Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9: e1003211.
CrossRef | PubMed | PubMed |

[46]  Sood N, Wagner Z, Jaycocks A, Drabo E, Vardavas R. Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles county. Clin Infect Dis 2013; 56: 1789–96.
CrossRef | PubMed | PubMed |

[47]  Jansson J, Wilson DP, Carr A, Petoumenos K, Boyd MA. Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV. AIDS 2012; 27: 1245–51.
CrossRef |

[48]  Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, et al Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society –USA panel. JAMA 2010; 304: 321–33.
CrossRef | CAS | CAS | PubMed | PubMed |

[49]  Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21: 965–71.
CrossRef | CAS | CAS | PubMed | PubMed |

[50]  Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res 2010; 85: 201–9.
CrossRef | CAS | CAS | PubMed | PubMed |

[51]  DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. The Lancet 2008; 371: 1417–1426.

Subscriber Login

Legal & Privacy | Contact Us | Help


© CSIRO 1996-2016